NCT07146100 Long-term Follow-up Study to Evaluate Participants With Chronic Hepatitis B (CHB) Previously Treated With AHB-137 Injection
| NCT ID | NCT07146100 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ausper Biopharma Co., Ltd. |
| Condition | Chronic Hepatitis B |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-08-28 |
| Primary Completion | 2028-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2025-08-28 with a primary completion date of 2028-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a prospective, open-label, multicenter long-term follow-up study to evaluate the durability of virologic response in subjects with chronic hepatitis B previously treated with AHB-137 injection.
Eligibility Criteria
Inclusion Criteria: * Capable of giving informed consent. * Participants who have previously received at least one dose of AHB-137 and achieved the complete of partial response in the parent study without rescue medication and who maintained response until the End of Study (EoS) visit in their parent study. Exclusion Criteria: * Participants who have/or are currently participating in another interventional clinical study since completing their treatment with AHB-137. * Suspected for cancer at screening or any condition required hospitalization during this study , or any condition which, in the opinion of the investigator or Medical Monitor, contraindicates their participation in this study.
Contact & Investigator
Jinlin Hou
PRINCIPAL INVESTIGATOR
Nanfang Hospital, Southern Medical University
Frequently Asked Questions
Who can join the NCT07146100 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Hepatitis B. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07146100 currently recruiting?
Yes, NCT07146100 is actively recruiting participants. Contact the research team at clinicaltrial@ausperbio.com for enrollment information.
Where is the NCT07146100 trial being conducted?
This trial is being conducted at Guangzhou, China, Changchun, China.
Who is sponsoring the NCT07146100 clinical trial?
NCT07146100 is sponsored by Ausper Biopharma Co., Ltd.. The principal investigator is Jinlin Hou at Nanfang Hospital, Southern Medical University. The trial plans to enroll 200 participants.